Liminatus Pharma Inc. (NASDAQ:LIMN) Short Interest Up 4,357.6% in February

Liminatus Pharma Inc. (NASDAQ:LIMN) was the target of a large increase in short interest during the month of February. As of February 13th, there was short interest totaling 2,677,258 shares, an increase of 4,357.6% from the January 29th total of 60,060 shares. Based on an average daily volume of 43,066,965 shares, the short-interest ratio is currently 0.1 days. Currently, 8.6% of the company’s shares are short sold. Currently, 8.6% of the company’s shares are short sold. Based on an average daily volume of 43,066,965 shares, the short-interest ratio is currently 0.1 days.

Liminatus Pharma Price Performance

Shares of NASDAQ LIMN traded up $0.01 during midday trading on Wednesday, hitting $0.24. The company’s stock had a trading volume of 1,682,279 shares, compared to its average volume of 13,576,730. The firm has a market capitalization of $7.42 million and a price-to-earnings ratio of -1.99. The business’s fifty day simple moving average is $0.73 and its two-hundred day simple moving average is $1.40. Liminatus Pharma has a 1 year low of $0.21 and a 1 year high of $33.66.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Wall Street Zen lowered shares of Liminatus Pharma from a “hold” rating to a “strong sell” rating in a report on Saturday, November 22nd. Weiss Ratings restated a “sell (e+)” rating on shares of Liminatus Pharma in a report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

About Liminatus Pharma

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.